Introduction
5-aminolevulinic acid (5-ALA) is a precursor of heme present in the majority of human cells. However, when applied to tumors, a photosensitizer protoporphyrin IX (PpIX) is overproduced and accumulated within cancer cells. This is thought to be due to aberrant negative-feedback mechanisms caused by the dysregulation of enzymes involved in the heme biosynthesis, although the underlying mechanisms are not completely understood [1] . PpIX induced by the treatment with 5-ALA therefore allows photodiagnosis (PD), an emerging modality for cancer detection prior to resection [2] . This fluorophore to the clinical use of 5-ALA, utilized as a PD surgical aid in high-grade gliomas resections [3] . The more lipophilic hexyl ester of 5-ALA has also been approved for local application to detect early human bladder cancer [4, 5] . The continuing development of 5-ALA in oncology has led to trials in PD of gastric cancer [6] , gastric cancer lymph nodes metastases [7] , cervical intraepithelial neoplasia [8] , ovarian cancer metastases [9] and also cancer stem cells [10] . Except for the use in PD of gliomas, 5-ALA has to be applied topically due to the unfavorable pharmacokinetics of the molecule [11] .
Attempts to improve the drug-like properties of the molecule have mostly focused on prodrug approaches. Most of the research has been focused on the modification of carboxylic group yielding a wide variety of esters of 5-ALA [12] . Eggleston and colleagues were the first to design double prodrugs of 5-ALA, where the amino group was derivatized with various N-acetyl amino acids. However, the 5-ALA peptide derivatives only show significant PpIX production in cell lines that express acyl peptide hydrolase [13] . We have recently reported two new phosphatase-sensitive double prodrug classes of 5-ALA with tunable release kinetics and robust fluorescence profiles in U87MG glioblastoma cancer cells [14] . This work has paved the way towards less toxic 5-ALA prodrugs. It demonstrates the feasibility of 5-ALA amino group chemical modification whilst retaining the pharmacological activity in cancer cells which is lacking in most other 5-amino modified derivatives of 5-ALA [15] . The discovery of novel 5-ALA double prodrugs is a way to progress 5-ALA-based PD as means of precise tumor detection.
To this end, β-glucuronidase-sensitive prodrugs of 5-ALA could yield a new cancer detection strategy.
β-glucuronidase is a tetrameric enzyme from glycosidase family localized in cell lysosomes [16] . Its physiological role is the hydrolysis of glucuronic acid-containing complex carbohydrates, such as glycosaminoglycans like chondroitin sulfate, heparan sulfate and dermatan sulphate [17] . Fishman and Anylan were the first to report the elevated activity of β-glucuronidase in tumor cells [18] . Their observations were further confirmed by others who found the elevated β-glucuronidase expression in microenvironment of lung, breast, ovarian, gastrointestinal cancer and melanomas [19] [20] [21] [22] . The concept of β-glucuronidase-sensitive prodrugs was first suggested by Tietze [23] . Since then, various cytotoxic agents including anthracyclines [21, [24] [25] [26] [27] , taxanes [28, 29] , 5-fluorouracil [30] , campothecin [31] [32] [33] [34] have been converted into β-glucuronidase-sensitive prodrugs liberated in solid tumors. The main aim of these modifications is reducing toxicity and targeted release of active principle.
Herein, we report the design, synthesis and in vitro evaluation of β-glucuronidase-sensitive prodrug of 5-ALA (Glu-ALA-Hex) for PD of cancers. The PD potential of the novel double prodrug was assessed by fluorescence-induction and confocal fluorescence microscopy after incubation with Glu-ALA-Hex in MCF7 breast adenocarcinoma cells.
Results and Discussion

Design
Prodrugs of 5-ALA have to successfully overcome the so-called stability-activity paradox of 5-ALA. [14] It stems from the fact that the prodrugs of 5-ALA with free amino group are unstable under physiological conditions [35] . Conversely, when the prodrug moiety is introduced to the same amino group, the prodrugs must be cleaved before entering the haem biosynthetic pathway to yield tetrapyrrolic porphyrins such as PpIX. This hypothesis is supported by experiments where 5-ALA amides generally fail to induce clinically relevant fluorescence of PpIX in vitro and in vivo in the absence of specific peptidases [36, 37] . Moreover, Berg and colleagues have shown that even a N-formyl ALA derivative failed to induce porphyrin synthesis [38] .
Glu-ALA-Hex construct (Figure 1 ) combines β-glucuronic acid trigger and 5-ALA in the form of hexyl ester (ALA-Hex). Both moieties are connected by a self-immolative 4-hydroxy-3-nitrobenzyl spacer attached to 5-ALA by carbamate group [39] . The whole construct needs to be stable under physiological conditions yet enzyme-sensitive. Rapid conversion by tumor β-glucuronidase yields sufficient amounts of 5-ALA for fluorescence PD. β-glucuronidase-sensitive prodrugs employing spacer groups between the active and the prodrug moieties have shown improved activation, drug-release and overall performance [40] [41] [42] [43] . The combined enzymatic-chemical mechanism of Glu-ALA-Hex activation is presented in Figure 2 . Tumor-specific cleavage by β-glucuronidase present in several cancers should further raise the level of tumor specificity of PD. 
Chemistry
The target molecule was synthesized in 7-steps (Scheme 1). The starting D-glucuronolactone was reacted with sodium metoxide in dry methanol followed by acetylation by acetic anhydride according to the procedure by Chern and colleagues to afford protected carbohydrate 1 [31] . Methyl 1,2,3,4-tetraacetyl-D-glucopyranuronate 1 was brominated with TiBr4 and reacted without purification with 4-hydroxy-3-nitro-benzaldehyde in the presence of Ag2O to yield D-glucuronyl derivative 2 in modest 44% yield. As reported the reaction afforded the -anomer selectively [44] . The aldehyde 2 was reduced by NaBH4 to benzyl alcohol derivative 3 in 72% yield. Under these reduction conditions the aromatic nitro group of the linker system was stable. Next, the ALA-Hex was introduced into the construct by 2-step one-pot procedure. First, 3 was activated with N,N′-disuccinimidyl carbonate which afforded Nsuccimidyl carbonate which was reacted in the second step with 2 eq. of ALA-Hex 4 to afford the fully protected compound 5 in very good yield (83 %). The final deprotection of 5 proved demanding since the molecule contains carbamate, glycoside and several ester bonds. The construct needs to contain these relatively liable bonds to ensure robust conversion into 5-ALA followed by the mitochondrial biosynthesis into fluorescent PpIX. Some of the tested conditions that failed to deprotect 5 included NaOMe/MeOH, aqueous LiOH, NaOH, Na2CO3 in MeOH and aqueous K2CO3. The total deprotection caused transesterification or degradation of the whole construct as detected by LC-MS. Finally, the successful deprotection was achieved using aqueous solution of MeOH and TEA at 70 °C for 2h. The Glu-ALA-Hex 6 was obtained after semi-preparative HPLC purification in good yield. 
Enzymatic activation
Glu-ALA-Hex is designed to release 5-ALA specifically in the presence of -glucuronidase in the tumor tissues. Following the rate-limiting enzymatic removal of glucuronic acid, the self-immolative linker cleaves spontaneously to give the ALA-Hex (Figure 2 ). The latter reaction is a 1,6-benzyl elimination reaction which proceeds rapidly [45] .
The sensitivity of the novel ALA prodrug 6 to -glucuronidase cleavage was assessed in vitro. It is well established that solid tumors, including breast, lung and gastrointestinal tract carcinomas, as well as melanomas have increased expression of β-glucuronidase as compared to normal tissues [22] . β-glucuronidase is present mainly in necrotic areas of the tumors. After cell necrosis, the liberation of lysosomal β-glucuronidase and the infiltration with activated neutrophils leads to increased levels of the enzyme in the extracellular matrix of the malignant tissues [49, 50] . As it was reported previously, in vitro incubation of β-glucuronidase-sensitive prodrugs of epirubicin, daunorubicin and doxorubicin with cancer cells did not lead to the complete release of the active compound [26, 51] . However, increased activity was observed when β-glucuronidase-sensitive prodrugs of daunorubicin or doxorubicin were incubated with cells in presence of an excess of active enzyme indicating complete liberation of the cytotoxic drugs [24, 51] . and endoplasmatic reticulum as main PpIX cellular distribution organelles [15, 52] . Our experiments also confirmed that PPIX does not co-localize with lysosomes ( Figure S2 ). It is noteworthy that some cells displayed apparent nuclear localization of PPIX (Figure 6b and 6c) . This is likely an experimental artefact as a consequence of the very weak fluorescence signal of PPIX. Therefore slight crosstalk between Hoechst 33342 and PPIX channels could not be avoided under the experimental conditions 
Conclusion
Glu-ALA-Hex was designed as β-glucuronidase-sensitive 5-ALA double prodrug. It was successfully 
Methyl 1-(4-hydroxymethyl-2-nitrophenyl)-2,3,4-triacetyl--D-glucopyranuronate (3). Compound
2 (232 mg, 0.48 mmol) was dissolved in DCM (10 mL) and MeOH (10 mL) and cooled to 0 °C. NaBH4 (30 mg, 0.72 mmol) was added slowly to the reaction mixture. After 30 min NH4Cl (20 mL) was added and extracted with DCM (3x15 mL). The organic phase was dried with Na2SO4 and evaporated to dryness. 
Hexyl 5-((((4-(-D-glucuronyl)-3-nitrobenzyl)oxy) carbonyl)amino)-4-oxopentanoate (6).
Compound 5 (100 mg, 0.138 mmol) was dissolved in a mixture of MeOH (65 mL), H2O (20 mL) and TEA (650 µL). The reaction was stirred at 70 °C for 2 h and then concentrated under reduced pressure.
The crude product was purified by RP-HPLC using H2O/AcN gradient containing 0.01% TFA. The 
PpIX fluorescence kinetic measurements
PpIX fluorescence kinetic measurements were performed as described previously [14] . 13 C and MS spectra of all the compounds described in this article.
